Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” second quarter 2024 ...

We recently compiled a list of the 10 Best Growth Stocks To Buy According To George Soros. In this article, we will look at ...

AstraZeneca released results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan, showing no statistically ...

Datopotamab deruxtecan is a TROP2-directed DXd ADC engineered by Daiichi Sankyo and co-developed by AstraZeneca and Daiichi Sankyo. The data pertaining to this compound will be presented at an ...

AstraZeneca (LSE:AZN) is navigating a period of robust growth and strategic challenges. Recent developments include an 18% ...

Intel jumps on reports of Apollo investment and Qualcomm takeover interest, Palantir and Dell join the S&P 500, and TSMC and Samsung reportedly mulling UAE chip megafactories. Here's what investors ...

The most recent trading session ended with Astrazeneca (AZN) standing at $78.38, reflecting a -0.66% shift from the previouse trading day's closing. The stock's change was less than the S&P 500's ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Check the time stamp on this data. Updated AI-Generated Signals for Astrazeneca Plc (AZN) available here: AZN.

AstraZeneca's Dato-DXd faces challenges in overall survival data but holds potential for approval with promising PFS benefits ...